Patent · US Active

RNA interference in ocular indications

US9095504B2 · kind B2 · utility

47Cited by

80References

10Claims

0Family size

Assignee

RXi Pharmaceuticals Corporation · US

Inventors

Lyn Libertine · Framingham, US
Anastasia Khvorova · Boulder, US
William Salomon · Worcester, US
Joanne Kamens · Newton, US
Dmitry Samarsky · Berlin, DE
Tod M. Woolf · Sudbury, US
James Cardia · Franklin, US

Key dates

Filing date	Mar 24, 2011
Grant date	Aug 4, 2015
Priority date	—
Expiry date	Mar 29, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/32
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to ocular administration of sd-rxRNA and rxRNAori molecules.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.